Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial

Autor: M Nishino, T Shinozaki, J Lash, N Takahashi, H Kokane, Béla Merkely, F Guimaraes, T Arakawa, C Zaidman, V Bugan, A Arouni, D Precoma, L Ermoshkina, A Pandey, D Kucera, I Efremov, L Younis, H Nagashima, C Chiang, M Ogunniyi, R Nilk, D Wang, T Haddad, M Zacharias, R Nischik, S Leslie, Mikhail Kosiborod, J Castriz, K Saito, I Weigmann, A Schabauer, A Kiyosue, M Hernandes, Charlotta Ljungman, Subodh Verma, Marc S. Sabatine, Y Khaykin, C Ince, S Iskander, Mark C. Petrie, G Drelich, R Lee, J Slaby, A Nikfarjam, M Kanwar, R Smik, Y Onishi, M Gadkari, M Suzuki, A Viera, S Matsuoka, F Poór, K Egstrup, M Bennett, Y Gu, L Maia, T Lewis, D Sinha, Jonathan G. Howlett, Andrej Dukát, J Shih, L Wu, O Montaña, D Peng, V Mehta, S Higashiue, S Rassi, Junbo Ge, S Mansour, H Nguyen, J Dong, E O’Meara, S Joseph, G Cursack, L Køber, G Reis, A Naik, M Schou, R Ahuad Guerrero, V Kostenko, Silvio E. Inzucchi, Scott D. Solomon, R Robles De Medina, E Vishneva, Y Didenko, D García Brasca, A Sosa Liprandi, M Bernstein, A Hedman, K Kuwahara, A Hirohata, Y Li, Michael Böhm, D Karageorgiev, B Al-Joundi, Jan Belohlavek, P Hajek, E Noori, J Spinar, S Sinha, M Milanova, B Groenemeijer, T Hashimoto, M Najenson, M Higuchi, C Brown, V Macek, S Mahal, B Merkely, K Lindmark, F Nasser-Sharif, N Botushanov, A Costard-Jäckle, S Hiroi, D Raev, L Lin, S Suzuki, N Toursarkissian, Rudolf A. de Boer, J Hove, W Huang, O Akinboboye, T Kadokami, Y Ivanova, N Koziolova, L Kantaros, L Pawłowicz, R Kuchar, K Chang, G Hamroff, C Staniloae, K Appel, L Spinarova, N Runev, J Lampart, N Jaffrani, Dapa-Hf Investigators, S Emani, L Antalik, Y Okumura, A Pereira, K Fujii, Y Hisamatsu, N Iliev, M Sandhu, S Vizel, M Pursley, Y Momiyama, A Ezhov, R Sawant, Z Zheng, M Hominal, S Mehta, B Han, K Shah, R Ściborski, J Saraiva, R Kawamura, R Witek, A Wada, C Majul, U Stephan, L Fu, David L. DeMets, M Tokmakova, D Martinez, L Jamriskova, Tzvetana Katova, E Schmidt, X Li, Eileen O'Meara, O Mayer, W Tseng, K Fujimoto, L Bellersen, C Wu, A Japp, J Sala, Mirta Diez, F Arantes, Kieran F. Docherty, Anna Maria Langkilde, R Cheng, H Chang, M Böhm, J Londono, J Walsh, Chern-En Chiang, R Mariankowski, A Mihov, Colin J. Petrie, M Mahapekar, Y Noguchi, Y Yasaka, Robert S. McKelvie, J Albisu, D Gupta, K Seki, Pardeep S. Jhund, C Király, A Al-Zoebi, H Ueno, I Malek, M Jardula, A Kazakov, I Lieber, F Franchi, D Avino, S Pereiro Gonzalez, P Wakefield, P Pimentel, T Kasai, E Fruehling, Olof Bengtsson, P Kopylov, S Uchikawa, X Guo, J Borges, S Tereschenko, F Azzari, J Selecky, S Sassone, J Vyselaar, S Lederman, J Howlett, Committees, E Vasconcellos, J Kostis, A Czigány, G Masszi, J Izzo, Z Járai, F Neuenschwander, L Tomasova, Mikaela Sjöstrand, C De Nooijer, Felipe Martinez, H Tsutsui, I Uchida, J Patel, A Arif, W Takahashi, M Nassif, K Moritani, M Mohri, J Shilko, Tereshchenko Sn, B Paolino, Z Wang, S Tanaka, João Pedro Ferreira, Y Takagi, H Jiang, A Maltcev, Piotr Ponikowski, V Bhargava, N Komiyama, W Dong, S Verma, S Weiss, L Busak, R Sotolongo, B Foley, C Hsia, John J.V. McMurray, T Mooe, R Gardner, N Cluigt, H Swart, N Spasova, Clare Murphy, K Harada, S Srivastava, P Olexa, B Bertolet, P Andrássy, M Petrie, Inder S. Anand, L Levinson, D Rupka, N Fujimoto, S Aksentiev, Y Hata, L Krylova, N Dzhaiani, R Korzeniak, T.Z. Maung, G Hickey, F Colombo Berra, X Zhang, Q Zhao, B Chompalova, D Avramov, M Asakura, A Hershson, G Mercau, N Takeyasu, J Menon, D Pevzner, T Nunohiro, T Katova, F Syed, W French, P Rossi, C Constance, Z Paltsman, K Tsukahara, A Gogov, M Liu, K Ilieva, I Majercak, Y Zhou, Vijay K. Chopra, T Anzai, F Mody, P Jhund, V Kothiwale, M Hartleib, S Zoet Nugteren, Z Li, J Drożdż, E Krcova, Lars Køber, A Galyavich, A Dincheva, R García Durán, D Hotchkiss, V Chopra, R Manshadi, T Greene, J Taborda, A Fernandez, E Lo, Pham Nguyen Vinh, G Gislason, K Sumii, G Lewis, L Nagy, S Genth-Zotz, J Liu, A Clark, P Leaes, A Wilke, Y Hayashi, J Belohlavek, Y Liang, S Szynal, M Van Hessen, T Kakuta, T Dalcoquio, J Skopek, S Karna, Q Tang, R Vijayaraghavan, K Fukui, X Lin, J Teel, S Nani, P Liu, D Vinanska, C Ljungman, Morten Schou, P Fulop, Y Katayama, D Song, L Yao, A Kimura, M Babapulle, D Kollarova, D Ho, E Fairman, S Deleon, V Pham, C Lindholm, T Kuramochi, S Boldueva, T Cimato, Y Ueda, T Shibasaki, H Takase, S Inoue, E MirekBryniarska, J Huang, D Aizenberg, R Chehayeb, J Van Eck, Y Pesant, Brian Claggett, H Do, I Hsieh, B Mikłaszewicz, R De Boer, Y Tomobuchi, J Carda, P Fong, N Kazemi, E Manenti, Y Komura, D Singal, Jarosław Drożdż, J Cha, T Nguyen, M Berk, E Hattori, B Kolomanov, Á Motyovszki, P Miękus, V Florea, T Lin, H Meno, G Simonis, L Videbæk, Y Dong, P Poirier, C Venugopal, D Tschöpe, M Deshpande, M Kellerer, L Chandra, K Ramanathan, C Lang, D Phaneuf, S Vladeva, H Kamiya, J Javier, Masahumi Kitakaze, M Talavera, Jose C. Nicolau, J Prokopczuk, B Truong, E Perna, W Sudnik, A Paraschos, H Sugino, S Banerjee, Akshay S. Desai, A Chernyavsky, H Luquez, P Nierop, P Udgire, G Caruso, M Slovenska, H Iseki

Publikováno v: JAMA Cardiol

Importance: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransport

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada7f7cf29c09c30f6ce473f3ab2c1ec
https://pubmed.ncbi.nlm.nih.gov/35234820

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index

Autor: Olof Bengtsson, Anna Maria Langkilde, Pardeep S. Jhund, Felipe Martinez, Morten Schou, Mirta Diez, Carly Adamson, Jan Bělohlávek, Lars Køber, Piotr Ponikowski, Mikhail Kosiborod, Charlotta Ljungman, Chern En Chiang, Andrej Dukát, Mikaela Sjöstrand, Marc S. Sabatine, John J.V. McMurray, Mark C. Petrie, Silvio E. Inzucchi, Jarosław Drożdż, Kieran F. Docherty, Daniel Lindholm, Jonathan G. Howlett, Scott D. Solomon

Publikováno v: Adamson, C, Jhund, P S, Docherty, K F, Bělohlávek, J, Chiang, C-E, Diez, M, Drożdż, J, Dukát, A, Howlett, J, Ljungman, C E A, Petrie, M C, Schou, M, Inzucchi, S E, Køber, L, Kosiborod, M N, Martinez, F A, Ponikowski, P, Sabatine, M S, Solomon, S D, Bengtsson, O, Langkilde, A M, Lindholm, D, Sjöstrand, M & McMurray, J J V 2021, ' Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index ', European Journal of Heart Failure, vol. 23, no. 10, pp. 1662-1672 . https://doi.org/10.1002/ejhf.2308

Aims: In heart failure with reduced ejection fraction (HFrEF), there is an ‘obesity paradox’, where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1043ac146495be6b395809defdb55f0b
https://curis.ku.dk/portal/da/publications/efficacy-of-dapagliflozin-in-heart-failure-with-reduced-ejection-fraction-according-to-body-mass-index(046cab69-7ee8-4291-976c-e6a578ad964c).html

271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF

Autor: Mirta Diez, Rudolf A. de Boer, David L. DeMets, Anna Maria Langkilde, Lars Køber, Mikaela Sjöstrand, Pardeep S. Jhund, Scott D. Solomon, Jan Belohlavek, Subodh Verma, Felipe Martinez, Piotr Ponikowski, Kieran F. Docherty, Mikhail Kosiborod, Chern-En Chiang, Charlotta Ljungman, Marc S. Sabatine, Andrej Dukát, John J.V. McMurray, Michael Böhm, Olof Bengtsson, Silvio E. Inzucchi

Publikováno v: Diabetes. 69

In DAPA-HF, the SGLT2 inhibitor (i) dapagliflozin (dapa) reduced worsening heart failure (HF) and cardiovascular death in 4744 patients (pts) with HF and reduced ejection fraction (HFrEF.) Only 45% had type 2 diabetes (T2D) at baseline. We evaluated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::206a043f73fd84daa2d59c5cc90e1380
https://doi.org/10.2337/db20-271-or

Unjustified discontinuation of statin preventive therapy - clinical consequences

Autor: Monika Laššánová, Milan Kriška, Jana Tisoňová, Andrej Dukát

Publikováno v: Klinická farmakologie a farmacie. 31:25-28

Statiny, zaraďovane do skupiny hypolipidemik, patria aj v sucasnosti k najcastejsie predpisovanej skupine lieciv. Stupajuci pocet studii jednoznacne potvrdzuje pri ich uživani významne zniženie morbidity a kardiovaskularnej mortality. Hoci existu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2911c74e8ccd49e42d7f3725a0a78e45
https://doi.org/10.36290/far.2017.036

The effects of body weight loss and gain on arterial hypertension control: an observational prospective study

Autor: Fedor Simko, Andrej Dukát, Ján Gajdošík, Matej Bendzala, Martin Caprnda, Peter Sabaka

Publikováno v: European Journal of Medical Research, Vol 22, Iss 1, Pp 1-7 (2017)
European Journal of Medical Research

Background Body weight changes are associated with significant variations in blood pressure (BP). Body mass modifications may, therefore, influence hypertension control in primary care. Methods Patients with a history of essential arterial hypertensi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47e2d2e27355d03540e42cbaec4bafe
http://link.springer.com/article/10.1186/s40001-017-0286-5